In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

ESC/EACTS revascularisation guidelines stress benefit of revascularisation in stable CAD

Chronic Ischaemic Heart Disease (IHD)


Barcelona, Spain – Saturday 30 August 2014: The therapeutic benefit of revascularisation in coronary artery disease (CAD) is emphasised in the 2014 ESC/EACTS revascularisation guidelines presented at ESC Congress by joint Task Force Chairs Professor Stephan Windecker (Switzerland) of the European Society of Cardiology (ESC) and Professor Philippe Kolh (Belgium) of the European Association for Cardio-Thoracic Surgery (EACTS). The joint guidelines are published today on-line in European Heart Journal (1), on the ESC Website (2), in EuroIntervention and in the European Journal of Cardio-Thoracic Surgery.
Previous ESC/EACTS Guidelines on myocardial revascularisation were published in 2010 (3). As part of their update, the Task Force performed a systematic review of the evidence including 100 trials in 93 553 patients with 262 090 patient years in the field of coronary revascularisation. “The key finding was that among patients with stable CAD, coronary artery bypass grafting (CABG) reduces the risk of death, myocardial infarction and repeat revascularisation compared with medical treatment,” Professors Kolh and Windecker said.

Professor Windecker said: “It was noteworthy that all stent based coronary revascularisation technologies were found to reduce the risk of repeat revascularisation, whereas new generation drug-eluting stents (DES) but no other percutaneous revascularisation technology improved survival compared with medical treatment”(4).


Following the results of the SYNTAX trial, the importance of this angiographic risk score is summarised and a useful algorithm to calculate the SYNTAX score is included in the document. Revascularisation is recommended based on symptomatic and prognostic indications. As compared with the previous 2010 edition, percutaneous coronary intervention (PCI) now assumes a similar Class and level of evidence as CABG in patients with proximal LAD disease (IA), simple left main disease (Syntax Score<22; IB) and simple three-vessel disease (Syntax Score<22, IB). Conversely, PCI was downgraded among patients with complex three-vessel disease (Syntax Score >22, IIIB) and left main disease (Syntax Score >32, IIIB). Based on the results of the FREEDOM trial, CABG is now the favoured revascularization therapy among diabetic patients with multivessel CAD and acceptable surgical risk (IA).
The new guidelines favour DES over bare metal stents in nearly all patients and lesion subsets. DES receive a Class I indication among patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. Professor Windecker said: “This upgrade is notable as there was concern about the use of first generation DES in the setting of STEMI but that has vanished with the advent of newer generation DES.”
 
Antithrombotic therapy in revascularisation is the largest chapter and had numerous updates. In patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), pretreatment with prasugrel before PCI is not recommended following the results of the ACCOAST trial. Recommendations on the duration of dual antiplatelet therapy (DAPT) after DES implantation in patients with stable CAD were changed to 6 months.

Professor Windecker said: “The new recommendation recognises that an extension beyond 6 months in patients with stable CAD is no longer necessary.”


In patients with STEMI, the use of bivalirudin after PCI has been downgraded from a Class I to a Class IIa recommendation. The Task Force agreed that the lower risk of bleeding observed in HORIZON-AMI is offset at least in part by the higher risk of periprocedural stent thrombosis shown in HORIZON-AMI, EUROMAX, HEAT and BRAVE 4 although there appears to be no impact on mortality and myocardial infarction.
A new chapter on the volume-outcome relationship for revascularisation procedures has been added. It provides the first guidance on minimal numbers of PCI and CABG procedures for physicians and institutions, plus recommendations for training to ensure high quality of care.

Professor Kolh concluded: “Revascularisation requires input from cardiologists, surgeons and interventionalists and our Task Force brought together experts in these fields. We hope the guidelines help clinicians make the best use of the revascularisation techniques currently available and improve quality of care across Europe.”

References

1) 2014 ESC/EACTS Guidelines on myocardial revascularisation. European Heart Journal. 2014 doi:10.1093/eurheartj/ehu278
2) Guidelines for Myocardial Revascularisation – ESC webpages
3) Guidelines on myocardial revascularisation. European Heart Journal. 2010;31:2501–2555. doi:10.1093/eurheartj/ehq277
4) Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ. 2014;348:g3859 doi: 10.1136/bmj.g3859 (Published 23 June 2014) ( full paper available in the ESC press kit)
Guidelines at ESC Congress - The 2014 ESC/EACTS Guidelines on myocardial revascularization will be featured in:
•    A dedicated session on Sunday 31 August  at 14:00
•    A Meet the Guidelines Task Force session on Sunday 31 August at 15:40
•    An ESC Guidelines 2014 overview session on Sunday 31 August at 11:00
•    An article in Congress News on Tuesday 2 September.

Notes to editor

The ESC Pocket Guidelines will be distributed in Barcelona in their paper version and the ESC Pocket Guidelines Application will be available to download for free from the Apple Store and Google Play.
The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies.
It is the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2014
The ESC Congress is currently the world's largest international congress in cardiovascular medicine.  The spotlight of this year's event is “innovation and the heart”.  ESC Congress 2014 takes place from 30 August to 3 September at the Fira Gran Via in Barcelona, Spain. For more information on ESC Congress 2014 contact the ESC Press Office.
To access all the scientific resources from the sessions during the congress, visit ESC Congress 365
ESC TV: Watch Prof Windecker's interview
About the ESC Clinical Practice Guidelines
ESC Guidelines aim to present all the relevant evidence on a particular clinical issue in order to help physicians to weigh the benefits and risks of a particular diagnostic or therapeutic procedure. They should be helpful in everyday clinical medical decision-making.
About the European Heart Journal (EHJ)
The European Heart Journal is the flagship journal of the European Society of Cardiology. It is published on behalf of the ESC by Oxford Journals, a division of Oxford University Press. Please acknowledge the journal as a source in any articles.
This press release accompanies a presentation at the ESC Congress 2014. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.